Epigenetics meets immune checkpoints

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 506-513

  Covre, Alessia ^a,b   Coral, Sandra ^a,b   Di Giacomo, Anna Maria ^a   Taverna, Pietro ^c   Azab, Mohammad ^c   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b Epigen Therapeutics Srl   (Italy)

^c ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCITIDINE; DNA METHYLTRANSFERASE INHIBITOR; GUADECITABINE; IMMUNOMODULATING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZACITIDINE; SGI-110;

ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; DEAMINATION; DEMETHYLATION; DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SOLID TUMOR; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS;

EID: 84929159881     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.003     Document Type: Review

References (33)

1. S. Sharma, T.K. Kelly, and P.A. Jones Epigenetics in cancer Carcinogenesis 31 1 2010 27 36
2. L. Sigalotti, E. Fratta, S. Coral, and M. Maio Epigenetic drugs as immunomodulators for combination therapies in solid tumors Pharmacol Ther 142 3 2014 339 350
3. E. Fratta, L. Sigalotti, and F. Colizzi Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma J Cell Physiol 223 2 2010 352 358
4. E. Fratta, S. Coral, and A. Covre The biology of cancer testis antigens: putative function, regulation and therapeutic potential Mol Oncol 5 2 2011 164 182
5. S. Coral, L. Sigalotti, and M. Altomonte 5-Aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications Clin Cancer Res 8 8 2002 2690 2695
6. A. Mittelman, G.Z. Chen, G.Y. Wong, C. Liu, S. Hirai, and S. Ferrone Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma Clin Cancer Res 1 7 1995 705 713
7. M. Campoli, and S. Ferrone HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance Oncogene 27 45 2008 5869 5885
8. E. Fonsatti, H.J. Nicolay, and L. Sigalotti Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications Clin Cancer Res 13 11 2007 3333 3338
9. S. Coral, L. Sigalotti, and F. Colizzi Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications J Cell Physiol 207 1 2006 58 66
10. S. Coral, L. Sigalotti, A. Covre, H.J.M. Nicolay, P.G. Natali, and M. Maio 5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story Cancer Res 67 6 2007 2900
11. S. Coral, A. Covre, and H.J. Nicolay Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications Br J Cancer 107 7 2012 1116 1124
12. M. Karahoca, and R.L. Momparler Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy Clin Epigenetics 5 1 2013 3
13. C.B. Yoo, S. Jeong, and G. Egger Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides Cancer Res 67 13 2007 6400 6408
14. S. Coral, G. Parisi, and H.J. Nicolay Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide Cancer Immunol Immunother 62 3 2013 605 614
15. Jueliger S, Lyons J, Lewin J, Azab M, Taverna P. Identification of novel biomarker candidates for the treatment outcome prediction of SGI-110, a novel DNA hypomethylating agent, in AML patients using differential methylation hybridization (DMH) Technology. Clinical Epigenetics International Meeting, March 6-7, 2014, Duesseldorf, Germany.
16. J.C. Chuang, S.L. Warner, and D. Vollmer S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth Mol Cancer Ther 9 5 2010 1443 1450
17. Taverna P, Scholl J, Shi C, Oganesian A, Redkar S, Azab M. Abstract 4076:SGI-110, a novel subcutaneous (SC) second generation DNA hypomethylating agent achieves improved pharmacodynamics (PD), safety and pharmacokinetics (PK) in comparison to IV decitabine in a non-human primate in vivo study. Proceedings: AACR 103rd Annual Meeting. Mar 31-Apr 4, 2012; Chicago, IL. Cancer Res. 2012;72:4076
18. F. Fang, J. Munck, and J. Tang The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer Clin Cancer Res 20 24 2014 6504 6516
19. Y. Wang, H. Cardenas, and F. Fang Epigenetic targeting of ovarian cancer stem cells Cancer Res 74 17 2014 4922 4936
20. L. Sigalotti, E. Fratta, and S. Coral Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications J Cell Physiol 212 2 2007 330 344
21. A.R. Karpf, A.W. Lasek, T.O. Ririe, A.N. Hanks, D. Grossman, and D.A. Jones Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine Mol Pharmacol 65 1 2004 18 27
22. P. Srivastava, B.E. Paluch, and J. Matsuzaki Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts Leuk Res. 38 11 2014 1332 1341
23. A.S. Yang, M.R. Estecio, K. Doshi, Y. Kondo, E.H. Tajara, and J.P. Issa A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements Nucleic Acids Res 32 3 2004 e38
24. H.M. Kantarjian, G.J. Roboz, and D.A. Rizzieri Results from the dose escalation phase of a randomized phase 1-2 first-in-human (FIH) study of SGI-110, a novel low volume stable subcutaneous (SC) second generation hypomethylating agent (HMA) in patients with relapsed/refractory MDS and AML Blood (ASH Annual Meeting Abstracts) 120 2012 414
25. H.M. Kantarjian, Y. Oki, and G. Garcia-Manero Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 109 1 2007 52 57
26. Roboz GJ, Issa JP, Rizzieri D, et al. DNA demethylation activity over time and safety of 3 different dose-escalation regimens of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory patients with MDS and AML. (ASH Annual Meeting Abstracts). Blood. 122(21):1548.
27. H.M. Kantarjian, E. Jabbour, and K. Yee First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Blood (ASH Annual Meeting Abstracts) 122 2013 497
28. Yee K, Daver N, Kropf P, et al. Results of a randomized multicenter phase 2 study of a 5-day regimen of SGI-110, a novel hypomethylating agent, in treatment-naïve elderly acute myeloid leukemia not eligible for intensive therapy. Oral presentation at 19th Congress of the European Hematology Association (EHA); Jun 12-15; Milan, Italy; abstract 5647.
29. Griffiths E, Kantarjian H, Roboz G, et al. First results of a Phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML). Proceedings of the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO); May 30-June 3; Chicago, IL; abstract 3074.
30. M. Maio, G. Choy, and A. Covre Immunomodulatory activity of SGI-110, a second generation hypomethylating agent. Proceedings of the 11th International Congress on Targeted Anticancer Therapies (TAT. 2013), 4-6 March 2013, Paris, France Ann Oncol 24 suppl 1 2013 i8 i9
31. A. Covre, G. Parisi, and H.J. Nicolay In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10 2013 AACR Washington, DC. Philadelphia, PA
32. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
33. M. Maio, A.M. Di Giacomo, C. Robert, and A.M. Eggermont Update on the role of ipilimumab in melanoma and first data on new combination therapies Curr Opin Oncol 25 2 2013 166 172